165 MET, ECD shedding, and loss of E-cadherin Supplementary table 8: Sensitivity, specificity, positive predictive and negative predictive value, accuracy and AUC of D1C2 uniform positive staining pattern in view of survival analyses with respect to DFS for patients showing overall more C- than N-terminal MET immunoreactivity (n=152). Positive test result was set at ≥ 12.5% D1C2 uniform positivity Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) AUC (95% CI) Cancers showing overall more C- than N-terminal MET immunoreactivity 64.1 58.1 61.7 60.6 61.2 0.61 (0.52; 0.70) Supplementary table 9: Results of performed ROC curve analyses in view of determining the cut off for percentage of cancer cells showing the uniform negative staining pattern for NCH-38 in view of survival analyses for OS for patients showing overall more C- than N-terminal MET immunoreactivity using Youden’s J statistic (n=152). Area Std. error Asymptotic sig. Asymptotic 95% confidence interval Lower bound Upper bound Results ROC curve used to determine the maximal value of the Youden index to determine the optimal cut-off for % of cancer cells showing the uniform negative staining pattern for NCH-38 in view of survival analyses 0.61 0.047 0.017 0.52 0.71 Results ROC curve obtained using the optimal cut off of 8.75 cancer cells showing the uniform negative staining pattern for NCH-38 0.61 0.046 0.027 0.51 0.70 Supplementary table 10: Sensitivity, specificity, positive predictive and negative predictive value, accuracy and AUC of NCH-38 uniform negative staining pattern in view of survival analyses with respect to OS for patients showing overall more C- than N-terminal MET immunoreactivity (n=152). Positive test result was set at ≥ 8.75% NCH-38 uniform negativity Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) AUC (95% CI) Cancers showing overall more C- than N-terminal MET immunoreactivity 67.7 53.3 50.0 70.6 59.2 0.61 (0.51; 0.70) 5
RkJQdWJsaXNoZXIy MTk4NDMw